In this study, we examined whether radiolabeled acetate uptake can predict therapeutic outcome of FASN-targeted therapy using human prostate cancer cell lines to demonstrate applicability of [1-11C]acetate PET as a predictor of FASN-targeted therapy outcome. The gene discussed is FASN; the disease is prostate cancer.